Innovent and AnHeart Therapeutics Report the NMPA’s Acceptance of Second NDA for Taletrectinib to Treat Lung Cancer
Shots:
- The NMPA has accepted second NDA of taletrectinib adipate capsule for the 1L treatment of locally advanced or metastatic ROS1+ NSCLC adult patients previously untreated with ROS1 TKIs
- Both the NDAs were supported by the data from P-II (TRUST-I) study highlighted at the European Lung Cancer Congress (ELCC) 2023 and additional data from TRUST-I is planned to be presented at an upcoming medical meeting in 2024. The first NDA for the drug was accepted in Nov 2023 and was granted priority review for the same indication
- Taletrectinib is an orally administered, brain-penetrating, selective, next-generation ROS1 inhibitor indicated for the treatment of NSCLC
Ref: Innovent | Image: Innovent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
